These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38671580)

  • 1. An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.
    Fleischer T; Haugen MH; Ankill J; Silwal-Pandit L; Børresen-Dale AL; Hedenfalk I; Hatschek T; Tost J; Engebraaten O; Kristensen VN
    Mol Oncol; 2024 Aug; 18(8):2042-2059. PubMed ID: 38671580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
    Gampenrieder SP; Rinnerthaler G; Hackl H; Pulverer W; Weinhaeusel A; Ilic S; Hufnagl C; Hauser-Kronberger C; Egle A; Risch A; Greil R
    Theranostics; 2018; 8(8):2278-2288. PubMed ID: 29721079
    [No Abstract]   [Full Text] [Related]  

  • 3. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.
    Lindholm EM; Ragle Aure M; Haugen MH; Kleivi Sahlberg K; Kristensen VN; Nebdal D; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Mol Oncol; 2019 Oct; 13(10):2278-2296. PubMed ID: 31402562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
    Selli C; Turnbull AK; Pearce DA; Li A; Fernando A; Wills J; Renshaw L; Thomas JS; Dixon JM; Sims AH
    Breast Cancer Res; 2019 Jan; 21(1):2. PubMed ID: 30616553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Pedersen CA; Cao MD; Fleischer T; Rye MB; Knappskog S; Eikesdal HP; Lønning PE; Tost J; Kristensen VN; Tessem MB; Giskeødegård GF; Bathen TF
    Breast Cancer Res; 2022 Jun; 24(1):43. PubMed ID: 35751095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Pineda B; Diaz-Lagares A; Pérez-Fidalgo JA; Burgués O; González-Barrallo I; Crujeiras AB; Sandoval J; Esteller M; Lluch A; Eroles P
    Clin Epigenetics; 2019 Feb; 11(1):33. PubMed ID: 30786922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
    Höglander EK; Nord S; Wedge DC; Lingjærde OC; Silwal-Pandit L; Gythfeldt HV; Vollan HKM; Fleischer T; Krohn M; Schlitchting E; Borgen E; Garred Ø; Holmen MM; Wist E; Naume B; Van Loo P; Børresen-Dale AL; Engebraaten O; Kristensen V
    Genome Med; 2018 Nov; 10(1):92. PubMed ID: 30497530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
    Haugen MH; Lingjærde OC; Hedenfalk I; Garred Ø; Borgen E; Loman N; Hatschek T; Børresen-Dale AL; Naume B; Mills GB; Mælandsmo GM; Engebraaten O
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
    Silwal-Pandit L; Nord S; von der Lippe Gythfeldt H; Møller EK; Fleischer T; Rødland E; Krohn M; Borgen E; Garred Ø; Olsen T; Vu P; Skjerven H; Fangberget A; Holmen MM; Schlitchting E; Wille E; Nordberg Stokke M; Moen Vollan HK; Kristensen V; Langerød A; Lundgren S; Wist E; Naume B; Lingjærde OC; Børresen-Dale AL; Engebraaten O
    Clin Cancer Res; 2017 Aug; 23(16):4662-4670. PubMed ID: 28487444
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.
    Li B; Jiang C; Xu Y; Fan X; Yang L; Zou B; Fan B; Wang L
    BMC Cancer; 2022 Jul; 22(1):828. PubMed ID: 35906610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
    Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
    PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
    Nome ME; Euceda LR; Jabeen S; Debik J; Bathen TF; Giskeødegård GF; Taskén KA; Maelandsmo GM; Halvorsen B; Yndestad A; Borgen E; Garred Ø; Aukrust P; Ueland T; Engebraaten O; Kristensen VN; Tekpli X
    Int J Cancer; 2020 Jan; 146(1):223-235. PubMed ID: 31444972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
    von der Lippe Gythfeldt H; Lien T; Tekpli X; Silwal-Pandit L; Borgen E; Garred Ø; Skjerven H; Schlichting E; Lundgren S; Wist E; Naume B; Kristensen V; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Int J Cancer; 2020 Nov; 147(9):2515-2525. PubMed ID: 32488909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.
    Trimarchi MP; Mouangsavanh M; Huang TH
    Chin J Cancer; 2011 Nov; 30(11):749-56. PubMed ID: 22035855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
    Han R; Wang G; Zhang Y; Zhao X
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.
    Hsu PC; Kadlubar SA; Siegel ER; Rogers LJ; Todorova VK; Su LJ; Makhoul I
    PLoS One; 2020; 15(4):e0230248. PubMed ID: 32298288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.